Similar articles

• Prognostic utility of B-type natriuretic peptide assessment in stable low-risk outpatients with nonischemic cardiomyopathy after decompensated heart failure.

  Nishii M, Inomata T, Takehana H, Naruke T, Yanagisawa T, Moriguchi M, Takeda S, Izumi T. Nishii M, et al. J Am Coll Cardiol. 2008 Jun 17;51(24):2329-35. doi: 10.1016/j.jacc.2007.11.085. J Am Coll Cardiol. 2008. PMID: 18549918
• Natriuretic peptides in heart failure: their role in daily practice.

  Loboz-Grudzień K, Jaroch J. Loboz-Grudzień K, et al. Cardiol J. 2009;16(1):1-3. Cardiol J. 2009. PMID: 19130409 No abstract available.
• Are multiple biomarker testing strategies ready for prime time in heart failure?

  Lee DS, Tu JV. Lee DS, et al. Circ Heart Fail. 2009 Sep;2(5):387-8. doi: 10.1161/CIRCHEARTFAILURE.109.898429. Circ Heart Fail. 2009. PMID: 19808366 No abstract available.
• The role of b-type natriuretic peptide in heart failure management.

  Newton PJ, Betihavas V, Macdonald P. Newton PJ, et al. Aust Crit Care. 2009 Aug;22(3):117-23. doi: 10.1016/j.aucc.2009.06.001. Epub 2009 Jul 8. Aust Crit Care. 2009. PMID: 19589695 Review.
• [Natriuretic cardiac hormones. Clinical use in heart failure].

  Nielsen SJ, Gøtze JP, Raymond IE, Grønning BA, Kirk V, Bay-Nielsen M, Hildebrandt PR, Aldershvile J. Nielsen SJ, et al. Ugeskr Laeger. 2004 Jan 19;166(4):248-53. Ugeskr Laeger. 2004. PMID: 14964102 Review. Danish. No abstract available.